Related Experiment Video
Updated: Sep 24, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies
1Cerrahpaşa Medical Faculty, Istanbul University, GETAM, Turkey. diyolog@superonline.com
Insights
Valproate therapy in epileptic children significantly altered antioxidant systems, increasing lipid peroxidation and decreasing glutathione peroxidase over two years. Carbamazepine showed less impact on these antioxidant markers in children with epilepsy.
Area of Science:
- Biochemistry
- Pediatric Neurology
- Pharmacology
Background:
- Epilepsy affects children's neurological function.
- Antiepileptic drugs (AEDs) are crucial for managing epilepsy.
- Understanding AEDs' impact on antioxidant systems is vital for pediatric care.
Purpose of the Study:
- To measure changes in antioxidant systems in epileptic children on valproate or carbamazepine monotherapy.
- To compare the effects of valproate and carbamazepine on erythrocyte glutathione, glutathione peroxidase, superoxide dismutase, and serum lipid peroxidation.
- To assess long-term (2-year) effects of these AEDs on antioxidant status.
Main Methods:
- Compared antioxidant markers in 27 epileptic children and 25 healthy controls.
- Administered valproate (n=14) or carbamazepine (n=13) monotherapy to epileptic children.
- Measured erythrocyte glutathione, glutathione peroxidase, superoxide dismutase, and serum lipid peroxidation at baseline, 13, and 24 months.
Main Results:
- Valproate therapy increased lipid peroxidation and decreased glutathione peroxidase in epileptic children compared to controls and baseline.
- Superoxide dismutase levels increased during the first year of valproate therapy.
- Carbamazepine therapy showed increased lipid peroxidation only compared to controls, not baseline, and increased superoxide dismutase in the second year.
Conclusions:
- Valproate therapy significantly affected children's antioxidant systems more than carbamazepine over two years.
- AEDs can impact the delicate balance of antioxidant defense mechanisms in pediatric epilepsy.
- Further research is needed to explore long-term implications and alternative treatments.
Abstract:
The aim of this study was to measure changes in the antioxidant systems of epileptic children who had been receiving either valproate or carbamazepine monotherapy for 2 years. For this purpose, levels of erythrocyte glutathione, glutathione peroxidase, superoxide dismutase, and serum lipid peroxidation in 25 healthy children and 27 children who had previously been diagnosed as having epilepsy but who had not, prior to the study, received antiepileptic drugs were tested. Of the 27 epileptic children, 14 were given valproate, and the remaining 13 were given carbamazepine; these tests were repeated in the 13th and 24th months of treatment. The results showed that, during valproate therapy, the lipid peroxidation levels of the epileptic children increased and the glutathione peroxidase levels decreased in comparison with those levels recorded in the control and pretreatment groups. In addition, the superoxide dismutase levels were found to be increased during the first year of valproate therapy when compared with those of the pretreatment group. However, during carbamazepine therapy, lipid peroxidation levels increased when compared with the control group only, not the pretreatment group. Furthermore, the results showed that during the second year of treatment, the superoxide dismutase levels of the children receiving carbamazapine monotherapy were found to be higher than those of both the control and pretreatment groups. From these results, it can be concluded that the antioxidant systems of the children who had been receiving valproate therapy during the 2 years were more significantly affected than those of the children who had been receiving carbamazepine.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy ll: Types

